{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:57:23Z","timestamp":1762869443091},"reference-count":22,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.3960\/jslrt.24035","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T22:31:43Z","timestamp":1727476303000},"page":"261-267","source":"Crossref","is-referenced-by-count":3,"title":["Salivary gland swelling as a characteristic manifestation of local                    cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell                    therapy: A case series"],"prefix":"10.3960","volume":"64","author":[{"given":"Saki","family":"Kawase","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Masuda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kubota","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahide","family":"Shindo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misa","family":"Nakayasu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Shiozawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Hirai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haryoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Koda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University                            School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Schuster                            SJ,                                Bishop                            MR,                                Tam                            CS                    <i>et al.<\/i> Tisagenlecleucel in adult relapsed or refractory diffuse                    large B-cell lymphoma. N Engl J Med. 2019; 380: 45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Locke                            FL,                                Ghobadi                            A,                                Jacobson                            CA                    <i>et al.<\/i> Long-term safety and activity of axicabtagene ciloleucel                    in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase                    1-2 trial. Lancet Oncol. 2019; 20: 31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Abramson                            JS,                                Palomba                            ML,                                Gordon                            LI                    <i>et al.<\/i> Lisocabtagene maraleucel for patients with relapsed or                    refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless                    design study. Lancet. 2020; 396: 839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Lee                            DW,                                Santomasso                            BD,                                Locke                            FL                    <i>et al.<\/i> ASTCT consensus grading for cytokine release syndrome                    and neurologic toxicity associated with immune effector cells. Biol Blood Marrow                    Transplant. 2019; 25: 625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Jin                            A,                                Feng                            J,                                Wang                            Z                    <i>et al.<\/i> Severe dyspnea caused by rapid enlargement of cervical                    lymph node in a relapsed\/refractory B-cell lymphoma patient following chimeric                    antigen receptor T-cell therapy. Bone Marrow Transplant. 2019; 54:                    969-972.","DOI":"10.1038\/s41409-018-0412-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Luan                            C,                                Zhou                            J,                                Wang                            H                    <i>et al.<\/i> Case report: Local cytokine release syndrome in an acute                    lymphoblastic leukemia patient after treatment with chimeric antigen receptor                    T-cell therapy: A possible model, literature review and perspective. Front                    Immunol. 2021; 12: 707191.","DOI":"10.3389\/fimmu.2021.707191"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Shima                            H,                                Kurosawa                            T,                                Oikawa                            H                    <i>et al.<\/i> Cervical edema extending to the larynx as local cytokine                    release syndrome following chimeric antigen receptor T-cell therapy in a boy                    with refractory acute lymphoblastic leukemia. Case Rep Oncol. 2022; 15:                    257-262.","DOI":"10.1159\/000522669"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Inoue                            Y,                                Fujino                            T,                                Chinen                            S                    <i>et al.<\/i> Cervical local cytokine release syndrome following                    chimeric antigen receptor T-cell therapy in patients with relapsed or refractory                    diffuse large B-cell lymphoma. Cureus. 2023; 15:                        e38905.","DOI":"10.7759\/cureus.38905"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ko                            JS,                                Lee                            JH,                                Yoon                            DH                    <i>et al.<\/i> CT demonstration of local cytokine-release syndrome                    involving the head and neck following chimeric antigen receptor T cell infusion                    therapy. Korean J Radiol. 2024; 25: 399-402.","DOI":"10.3348\/kjr.2023.1100"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Nakanishi                            Y,                                Marumo                            Y,                                Ri                            M                    <i>et al.<\/i> Laryngeal edema as a symptom of local cytokine release                    syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple                    myeloma. Int J Hematol. 2023; 118: 647-651.","DOI":"10.1007\/s12185-023-03633-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Coiffier                            B,                                Thieblemont                            C, Van                                Den Neste                            E                    <i>et al.<\/i> Long-term outcome of patients in the LNH-98.5 trial, the                    first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in                    DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood.                    2010; 116: 2040-2045.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Oki                            Y,                                Ogura                            M,                                Kato                            H                    <i>et al.<\/i> Phase II study of a salvage regimen using                    cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab                    in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. Cancer                    Sci. 2008; 99: 179-184.","DOI":"10.1111\/j.1349-7006.2007.00662.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sehn                            LH,                                Herrera                            AF,                                Flowers                            CR                    <i>et al.<\/i> Polatuzumab vedotin in relapsed or refractory diffuse                    large B-cell lymphoma. J Clin Oncol. 2020; 38: 155-165.","DOI":"10.1200\/JCO.19.00172"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Greenbaum                            U,                                Strati                            P,                                Saliba                            RM                    <i>et al.<\/i> CRP and ferritin in addition to the EASIX score predict                    CAR-T-related toxicity. Blood Adv. 2021; 5: 2799-2806.","DOI":"10.1182\/bloodadvances.2021004575"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Rohatiner                            A. Report on a                    workshop convened to discuss the pathological and staging classifications of                    gastrointestinal tract lymphoma. Ann Oncol. 1994; 5: 397-400.","DOI":"10.1093\/oxfordjournals.annonc.a058869"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tilly                            H,                                Morschhauser                            F,                                Sehn                            LH                    <i>et al.<\/i> Polatuzumab vedotin in previously untreated diffuse                    large B-cell lymphoma. N Engl J Med. 2022; 386: 351-363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Crump                            M,                                Kuruvilla                            J,                                Couban                            S                    <i>et al.<\/i> Randomized comparison of gemcitabine, dexamethasone, and                    cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before                    autologous stem-cell transplantation for relapsed and refractory aggressive                    lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014; 32: 3490-3496.","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Nakaya                            A,                                Fujita                            S,                                Satake                            A                    <i>et al.<\/i> Trend of salvage treatment in diffuse large B cell                    lymphoma in the outpatient chemotherapy era. Mol Clin Oncol. 2019; 11:                    557-562.","DOI":"10.3892\/mco.2019.1930"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Mart\u00edn                            A,                                Conde                            E,                                Arnan                            M                    <i>et al.<\/i> R-ESHAP as salvage therapy for patients with relapsed or                    refractory diffuse large B-cell lymphoma: the influence of prior exposure to                    rituximab on outcome. A GEL\/TAMO study. Haematologica. 2008; 93:                    1829-1836.","DOI":"10.3324\/haematol.13440"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Wei                            J,                                Liu                            Y,                                Wang                            C                    <i>et al.<\/i> The model of cytokine release syndrome in CAR T-cell                    treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020;                    5: 134.","DOI":"10.1038\/s41392-020-00256-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Yakoub-Agha                            I,                                Chabannon                            C,                                Bader                            P                    <i>et al.<\/i> Management of adults and children undergoing chimeric                    antigen receptor T-cell therapy: best practice recommendations of the European                    Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation                    Committee of ISCT and EBMT (JACIE). Haematologica. 2020; 105:                    297-316.","DOI":"10.3324\/haematol.2019.229781"},{"key":"22","unstructured":"22 Thompson JA, Schneider BJ, Brahmer J,                        <i>et al.<\/i> Management of immunotherapy-related toxicities,                    Version 1.2024, NCCN Clinical Practice Guidelines in Oncology.                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/3\/64_24035\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T05:06:01Z","timestamp":1727499961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/3\/64_24035\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24035","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"type":"print","value":"1346-4280"},{"type":"electronic","value":"1880-9952"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"24035"}}